The DOI matches its Crossref record; 200 of the 201 references it cites were found in a registry or an index.
Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease
Open accessAbstract
Amyloid-β proteins (Aβ) of 42 (Aβ42) and 40 aa (Aβ40) accumulate as senile plaques (SP) and cerebrovascular amyloid protein deposits that are defining diagnostic features of Alzheimer's disease (AD). A number of rare mutations linked to familial AD (FAD) on the Aβ precursor protein (APP), Presenilin-1 (PS1), Presenilin- 2 (PS2), Adamalysin10, and other genetic risk factors for sporadic AD such as the ε4 allele of Apolipoprotein E (ApoE-ε4) foster the accumulation of Aβ and also induce the entire spectrum of pathology associated with the disease. Aβ accumulation is therefore a key pathological event and a prime target for the prevention and treatment of AD. APP is sequentially processed by β-site APP cleaving enzyme (BACE1) and γ-secretase, a multisubunit PS1/PS2-containing integral membrane protease, to generate Aβ. Although Aβ accumulates in all forms of AD, the only pathways known to be affected in FAD increase Aβ production by APP gene duplication or via base substitutions on APP and γ-secretase subunits PS1 and PS2 that either specifically increase the yield of the longer Aβ42 or both Aβ40 and Aβ42. However, the vast majority of AD patients accumulate Aβ without these known mutations. This led to proposals that impairment of Aβ degradation or clearance may play a key role in AD pathogenesis. Several candidate enzymes, including Insulin-degrading enzyme (IDE), Neprilysin (NEP), Endothelin-converting enzyme (ECE), Angiotensin converting enzyme (ACE), Plasmin, and Matrix metalloproteinases (MMPs) have been identified and some have even been successfully evaluated in animal models. Several studies also have demonstrated the capacity of γ-secretase inhibitors to paradoxically increase the yield of Aβ and we have recently established that the mechanism is by skirting Aβ degradation. This review outlines major cellular pathways of Aβ degradation to provide a basis for future efforts to fully characterize the panel of pathways responsible for Aβ turnover.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“cerebrospinal fluid (CSF) levels of the angiotensin-converting enzyme (ACE) are associated with Aβ levels81 and LOAD risk82, and studies show ACE can inhibit Aβ toxicity and aggregation83.”
From Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) · cites this paper as [83]
In the citing paper
“In the hippocampus of AD patients, the enzymes IDE, ACE and NEP had decreased activity.30”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Visse, R., & Nagase, H. (2003) · Circulation Research · doi:10.1161/01.res.0000070112.80711.3d · Cited by 4,575
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 2×
“tyl protease with an acid pH optimum, in an endosome where -secretase is also present and converts CTF to A [25, 45].”
BackgroundClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Rigat, B., Hubert, C., Alhenc-Gelas, F., Cambien, F., Corvol, P., & Soubrier, F. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114844 · Cited by 3,767
Structure and function of matrix metalloproteinases and TIMPs
Nagase, H., Visse, R., & MURPHY, G. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.12.002 · Cited by 3,507
2013 Alzheimer's disease facts and figures
Thies, W. H., & Bleiler, L. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,372
Research works printed but not linked: 1
- [23]Sambamurti K Greig NH Utsuki T Barnwell EL Sharma E Mazell C Targets for AD treatment: conflicting messages from gamma-secretase inhibitors J Neurochem 117 3 359 74 2011 21320126 PMC3076515
Cited by
Sorted by citations
Alzheimer Disease Genetics Consortium (ADGC), Kunkle, B. W., The European Alzheimer’s Disease Initiative (EADI), Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE), Genetic and Environmental Risk in AD/Defining Genetic, P. A. E. R. F. A. D. C. (., Grenier-Boley, B., Sims, R., Bis, J. C., Damotte, V., Naj, A. C., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0358-2 · Cited by 2,946
Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
“In the hippocampus of AD patients, the enzymes IDE, ACE and NEP had decreased activity.(30) AD model mice also showed the impaired Aβ degradation system.”
BackgroundPromoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing
Boland, B., Yu, W. H., Corti, O., Mollereau, B., Henriques, A., Bézard, E., Pastores, G., Rubinsztein, D. C., Nixon, R. A., Duchen, M. R., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.109 · Cited by 566
Genetic diversity fuels gene discovery for tobacco and alcohol use
Saunders, G., Wang, X., Chen, F., Jang, S.-K., Liu, M., Wang, C., Gao, S., Jiang, Y., Khunsriraksakul, C., Otto, J. M., et al. (2022) · Nature · doi:10.1038/s41586-022-05477-4 · Cited by 481
Role of Plant Derived Alkaloids and Their Mechanism in Neurodegenerative Disorders
Hussain, G., Rasul, A., Anwar, H., Aziz, N., Razzaq, A., Wei, W., Ali, M., Li, J., & Li, X. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.23247 · Cited by 352
β-Amyloid: the key peptide in the pathogenesis of Alzheimer’s disease
Sun, X., Chen, W., & Wang, Y. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00221 · Cited by 340
The identity and function of microglia in neurodegeneration
Song, W. M., & Colonna, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0212-1 · Cited by 308
Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment
Folch, J., Petrov, D., Ettcheto, M., Abad, S., Sánchez-López, E., García, M. L., Olloquequi, J., Beas-Zarate, C., Auladell, C., & Camins, A. (2016) · Neural Plasticity · doi:10.1155/2016/8501693 · Cited by 270
Lymphatic drainage system of the brain: A novel target for intervention of neurological diseases
Sun, B., Wang, L.-H., Yang, T., Sun, J., Mao, L., Yang, M., Yuan, H., Colvin, R. A., & Yang, X. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.08.007 · Cited by 264
Andrade, S., Ramalho, M. J., Loureiro, J. A., & Pereira, M. D. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092313 · Cited by 240
Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
Pardo-Moreno, T., González-Acedo, A., Rivas-Domínguez, A., García-Morales, V., García-Cozar, F. J., Ramos-Rodríguez, J. J., & Melguizo-Rodríguez, L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061117 · Cited by 239
Protein misfolding and aggregation in Alzheimer’s disease and type 2 diabetes mellitus
Ashraf, G., Greig, N., Khan, T., Hassan, I., Tabrez, S., Shakil, S., Sheikh, I., Zaidi, S., Akram, M., Jabir, N., et al. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140917095514 · Cited by 236
Self-citationIdentification of early pericyte loss and vascular amyloidosis in Alzheimer’s disease retina
Shi, H., Koronyo, Y., Rentsendorj, A., Regis, G. C., Sheyn, J., Fuchs, D.-T., Kramerov, A. A., Ljubimov, A. V., Dumitrascu, O. M., Rodriguez, A. R., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02134-w · Cited by 230
Recent progress of drug nanoformulations targeting to brain
Khan, A. R., Yang, X., Fu, M., & Zhai, G. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.004 · Cited by 216
Clearance of Amyloid Beta and Tau in Alzheimer’s Disease: from Mechanisms to Therapy
Xin, S.-H., Tan, L., Cao, X., Yu, J.-T., & Tan, L. (2018) · Neurotoxicity Research · doi:10.1007/s12640-018-9895-1 · Cited by 222
Kim, Y. H., Park, J., & Choi, Y. K. (2019) · Antioxidants · doi:10.3390/antiox8050121 · Cited by 211
Role of Prenatal Hypoxia in Brain Development, Cognitive Functions, and Neurodegeneration
Nalivaeva, N. N., Turner, A. J., & Zhuravin, I. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00825 · Cited by 181
Mitochondrial Dysfunction and Alzheimer’s Disease: Role of Microglia
Agrawal, I., & Jha, S. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00252 · Cited by 184
Pentkowski, N. S., Rogge-Obando, K., Donaldson, T. N., Bouquin, S. J., & Clark, B. J. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.05.005 · Cited by 177
Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy
Nalivaeva, N. N., & Turner, A. J. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14593 · Cited by 177
Melatonin and Autophagy in Aging-Related Neurodegenerative Diseases
Luo, F., Sandhu, A. F., Rungratanawanich, W., Williams, G. E., Akbar, M. D., Zhou, S., Song, B., & Wang, X. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197174 · Cited by 162
Millan, M. J. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.03.004 · Cited by 151
Therapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Pinheiro, L. M. V., & Faustino, C. M. C. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190321163438 · Cited by 144
Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions
Seto, M., Weiner, R. L., Dumitrescu, L., & Hohman, T. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00452-5 · Cited by 135
Koelsch, G. (2017) · Molecules · doi:10.3390/molecules22101723 · Cited by 128
Neprilysin Inhibition to Treat Heart Failure: A Tale of Science, Serendipity, and Second Chances
McMurray, J. J. V. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.250 · Cited by 125
Microbial involvement in Alzheimer disease development and progression
Bulgart, H. R., Neczypor, E. W., Wold, L. E., & Mackos, A. R. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00378-4 · Cited by 116
Cannon, J. A., Shen, L., Jhund, P. S., Kristensen, S. L., Køber, L., Chen, F., Gong, J., Lefkowitz, M. P., Rouleau, J. L., Shi, V. C., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.687 · Cited by 117
Targeting Renin–Angiotensin System Against Alzheimer’s Disease
Gebre, A. K., Altaye, B. M., Atey, T. M., Tuem, K. B., & Berhe, D. F. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00440 · Cited by 118
Sun, M., Ma, K., Wen, J., Wang, G., Zhang, C., Li, Q., Bao, X., & Wang, H. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190872 · Cited by 113
Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease
Madav, Y., Wairkar, S., & Prabhakar, B. R. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.01.004 · Cited by 122
Langenickel, T., Tsubouchi, C., Ayalasomayajula, S. P., Pal, P., Valentin, M., Hinder, M., Jhee, S. S., Gevorkyan, H., & Rajman, I. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12861 · Cited by 111
Mayer-Pröschel, M., Hogestyn, J. M., & Mock, D. J. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.226380 · Cited by 106
Folch, J., Ettcheto, M., Petrov, D., Abad, S., Pedrós, I., Marin, M., Olloquequi, J., & Camins, A. (2017) · Neurología (English Edition) · doi:10.1016/j.nrleng.2015.03.019 · Cited by 105
Mutations inMMEcause an autosomal‐recessive Charcot–Marie–Tooth disease type 2
Higuchi, Y., Hashiguchi, A., Yuan, J., Yoshimura, A., Mitsui, J., Ishiura, H., Tanaka, M., Ishihara, S., Tanabe, H., Nozuma, S., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24612 · Cited by 104
Chopra, N., Wang, R., Maloney, B., Nho, K. T., Beck, J. S., Pourshafie, N., Niculescu, A. B., Saykin, A. J., Rinaldi, C., Counts, S., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0610-2 · Cited by 101
Self-citationSalehpour, F., Khademi, M., Bragin, D. E., & DiDuro, J. O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23062975 · Cited by 106
Amylin at the interface between metabolic and neurodegenerative disorders
Lutz, T. A., & Meyer, U. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00216 · Cited by 97
Ou, Y., Yang, Y., Deng, Y., Zhang, C. M., Hu, H., Wu, B., Liu, Y., Wang, Y., Zhu, Y., Suckling, J., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01251-6 · Cited by 100
Wang, X., & Zheng, W. (2019) · The FASEB Journal · doi:10.1096/fj.201801751r · Cited by 97
Folch, J., Ettcheto, M., Petrov, D., Abad, S., Pedrós, I., Marin, M., Olloquequi, J., & Camins, A. (2015) · Neurología · doi:10.1016/j.nrl.2015.03.012 · Cited by 102
P‐glycoprotein: a role in the export of amyloid‐β in Alzheimer's disease?
Chai, A. B., Leung, G. K. F., Callaghan, R., & Gelissen, I. C. (2019) · FEBS Journal · doi:10.1111/febs.15148 · Cited by 100
Melatonin Treatment Enhances Aβ Lymphatic Clearance in a Transgenic Mouse Model of Amyloidosis
Pappolla, M. A., Matsubara, E., Vidal, R., Pacheco‐Quinto, J., Pöeggeler, B., Zagorski, M. G., & Sambamurti, K. (2018) · Current Alzheimer Research · doi:10.2174/1567205015666180411092551 · Cited by 83
Self-citationTzeng, T.-T., Chen, C.-C., Chen, C., Tsay, H.-J., Lee, L., Chen, W.-P., Shen, C.-C., & Shiao, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020598 · Cited by 86
Toda, N., & Okamura, T. (2016) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2016.07.001 · Cited by 79
Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow
Dolui, S., Detre, J. A., Gaussoin, S. A., Herrick, J. S., Wang, D. J. J., Tamura, M. K., Cho, M. E., Haley, W. E., Launer, L. J., Punzi, H. A., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.0074 · Cited by 76
Mechanisms of action of amyloid-beta and its precursor protein in neuronal cell death
Leong, Y. Q., Ng, K. Y., Chye, S. M., Ling, A. P. K., & Koh, R. Y. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-019-00516-y · Cited by 80
D’Mello, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115911 · Cited by 80
Al‐kuraishy, H. M., Jabir, M. S., Albuhadily, A. K., Al-Gareeb, A. I., & Rafeeq, M. F. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102084 · Cited by 75
Du, Y., Qu, J., Zhang, W., Bai, M., Zhou, Q., Zhang, Z., Li, Z., & Miao, J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.008 · Cited by 72
Autophagy Modulation as a Treatment of Amyloid Diseases
Mputhia, Z., Hone, E., Tripathi, T., Sargeant, T. J., Martins, R. N., & Bharadwaj, P. (2019) · Molecules · doi:10.3390/molecules24183372 · Cited by 69
Electrochemical Biosensors Based on Nanomaterials for Early Detection of Alzheimer’s Disease
Toyos‐Rodríguez, C., Alonso, F. J. G., & de la Escosura‐Muñiz, A. (2020) · Sensors · doi:10.3390/s20174748 · Cited by 69
Tryptophan metabolites modify brain Aβ peptide degradation: A role in Alzheimer’s disease?
Maître, M., Klein, C., Patte‐Mensah, C., & Mensah‐Nyagan, A. G. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101800 · Cited by 69
Metabolic Regulation of Glia and Their Neuroinflammatory Role in Alzheimer's Disease
Kumari, P., Sood, A., & Fernandes, V. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01147-7 · Cited by 68
Brain Renin–Angiotensin System as Novel and Potential Therapeutic Target for Alzheimer’s Disease
Loera‐Valencia, R., Eroli, F., Ptacek, S. G., & Maioli, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810139 · Cited by 67
Neuroprotective Effects of Ginsenoside Rf on Amyloid-β-Induced Neurotoxicity in vitro and in vivo
Du, Y., Fu, M., Wang, Y. T., & Dong, Z. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180251 · Cited by 66
Redox-Active Metal Ions and Amyloid-Degrading Enzymes in Alzheimer’s Disease
Kim, N., & Lee, H. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147697 · Cited by 67
Wang, R., Chopra, N., Nho, K. T., Maloney, B., Obukhov, A. G., Nelson, P. T., Counts, S., & Lahiri, D. K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01351-3 · Cited by 66
Self-citationLi, Q. S., & Muynck, L. D. (2021) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2021.100227 · Cited by 60
Laboratory evolution of a sortase enzyme that modifies amyloid-β protein
Podracky, C. J., An, C., DeSousa, A., Dorr, B. M., Walsh, D. M., & Liu, D. R. (2021) · Nature Chemical Biology · doi:10.1038/s41589-020-00706-1 · Cited by 61
Neuroprotective Mechanisms Mediated by CDK5 Inhibition
Mushtaq, G., Greig, N. H., Anwar, F., Al-Abbasi, F. A., Zamzami, M. A., Al-Talhi, H. A., & Kamal, M. A. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151124235028 · Cited by 66
Self-citationInsulin mediated novel therapies for the treatment of Alzheimer's disease
Dubey, S. K., Lakshmi, K. K., Krishna, K. V., Agrawal, M., Singhvi, G., Saha, R. N., Saraf, S., Saraf, S., Shukla, R., & Alexander, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117540 · Cited by 62
Landlinger, C., Oberleitner, L., Gruber, P., Noiges, B., Yatsyk, K., Santic, R., Mandler, M., & Staffler, G. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0369-6 · Cited by 60
Ubiquitin binds the amyloid β peptide and interferes with its clearance pathways
Bellia, F., Lanza, V., García‐Viñuales, S., Ahmed, I. M. M., Pietropaolo, A., Iacobucci, C., Malgieri, G., D’Abrosca, G., Fattorusso, R., Nicoletti, V. G., et al. (2019) · Chemical Science · doi:10.1039/c8sc03394c · Cited by 60
Zhang, J., Zhu, S., Jin, P., Huang, Y., Dai, Q., Zhu, Q., Wei, P., Yang, Z., Zhang, L., Liu, H., et al. (2020) · Theranostics · doi:10.7150/thno.50616 · Cited by 60
de la Monte, S. M., Tong, M., Daiello, L. A., & Ott, B. R. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180906 · Cited by 63
Yan, X., Liu, H., Hong, Y.-X., Meng, T., Du, J., & Chang, C. (2022) · Journal of Neurogenetics · doi:10.1080/01677063.2022.2028784 · Cited by 56
Genistein: A focus on several neurodegenerative diseases
Li, R., Robinson, M., Ding, X.-W., Geetha, T., Al‐Nakkash, L., Broderick, T. L., & Babu, J. R. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14155 · Cited by 57
Recent advancement in therapeutic strategies for Alzheimer’s disease: Insights from clinical trials
Khan, T., Waseem, R., Shahid, M., Ansari, J., Ahanger, I. A., Hassan, M. I., & Islam, A. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102113 · Cited by 60
Nuthakki, V. K., Sharma, A., Kumar, A., & Bharate, S. B. (2019) · Drug Development Research · doi:10.1002/ddr.21544 · Cited by 56
Association of Angiotensin II–Stimulating Antihypertensive Use and Dementia Risk
van Dalen, J. W., Marcum, Z. A., Gray, S. L., Barthold, D., van Charante, E. P. M., van Gool, W. A., Crane, P. K., Larson, E. B., & Richard, E. (2020) · Neurology · doi:10.1212/wnl.0000000000010996 · Cited by 56
Cho, G. M., Lee, S., Park, J. H., Kim, M. J., Park, K.-J., Choi, B. T., Shin, Y., Kim, N. G., & Shin, H. K. (2018) · The Journals of Gerontology Series A · doi:10.1093/gerona/gly240 · Cited by 53
Nuthakki, V. K., Mudududdla, R., Sharma, A., Kumar, A., & Bharate, S. B. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103062 · Cited by 52
Packer, M., & McMurray, J. J. V. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30969-2 · Cited by 51
Ribeiro, V. T., de Souza, L. C., & Silva, A. C. S. E. (2019) · Protein and Peptide Letters · doi:10.2174/0929866527666191230103739 · Cited by 50
High-fat diet impairs cognitive function of zebrafish
Meguro, S., Hosoi, S., & Hasumura, T. (2019) · Scientific Reports · doi:10.1038/s41598-019-53634-z · Cited by 50
Li, X., Cui, J., Yu, Y., Li, W., Hou, Y., Wang, X., Qin, D.-P., Zhao, C., Yao, X., Zhao, J., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151147 · Cited by 49
Future Therapeutics in Alzheimer’s Disease: Development Status of BACE Inhibitors
Evin, G. M. (2016) · BioDrugs · doi:10.1007/s40259-016-0168-3 · Cited by 52
Periodontitis and alzheimer´s disease
Sansores‐España, L. D., Carrillo-Ávila, A., Melgar‐Rodríguez, S., Díaz‐Zúñiga, J., & Martínez-Aguilar, V. M. (2020) · Medicina oral, patología oral y cirugía bucal · doi:10.4317/medoral.23940 · Cited by 53
Fronza, M. G., Alves, D. A. C., Praticò, D., & Savegnago, L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102033 · Cited by 47
Akhter, H., Huang, W.-T., van Groen, T., Kuo, H., Miyata, T., & Liu, R.-M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180241 · Cited by 49
Ahlemeyer, B., Halupczok, S., Rodenberg-Frank, E., Valerius, K.-P., & Baumgart‐Vogt, E. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170923 · Cited by 49
Alcendor, D. J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051490 · Cited by 47
Marcum, Z. A., Cohen, J. B., Zhang, C., Derington, C. G., Greene, T., Ghazi, L., Herrick, J. S., King, J. B., Cheung, A. K., Bryan, R. N., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.45319 · Cited by 47
Jorba, G., Aguirre‐Plans, J., Junet, V., Segú-Vergés, C., Ruiz, J. L., Pujol, A., Fernández‐Fuentes, N., Mas, J. M., & Oliva, B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228926 · Cited by 45
Sodium Butyrate Protects N2a Cells against Aβ Toxicity In Vitro
Sun, J., Yuan, B., Wu, Y., Gong, Y., Guo, W., Fu, S., Luan, Y., & Wang, W. (2020) · Mediators of Inflammation · doi:10.1155/2020/7605160 · Cited by 47
The multifaceted role of WNT signaling in Alzheimer’s disease onset and age-related progression.
Kostes, W. W., & Brafman, D. A. (2023) · Cells · doi:10.3390/cells12081204 · Cited by 43
Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
Dargad, R. R., Prajapati, M. R., Dargad Rohit, R., & Parekh, J. D. (2018) · Indian Heart Journal · doi:10.1016/j.ihj.2018.01.002 · Cited by 47
Klein, C., Roussel, G., Brun, S., Rusu, C., Patte‐Mensah, C., Maître, M., & Mensah‐Nyagan, A. G. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0640-z · Cited by 46
Pacheco-Quinto, J., Eckman, C., & Eckman, E. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.08.011 · Cited by 33
Marongiu, R. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00242 · Cited by 47
p38 MAPK Is a Major Regulator of Amyloid Beta-Induced IL-6 Expression in Human Microglia
Lin, H., Dixon, S. G., Hu, W., Hamlett, E. D., Jin, J., Ergul, A., & Wang, G. Y. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02909-0 · Cited by 43
Valsartan/Sacubitril for Heart Failure
Feldman, A. M., Haller, J. A., & DeKosky, S. T. (2015) · JAMA · doi:10.1001/jama.2015.17632 · Cited by 41
Meta-analysis of expression and function of neprilysin in Alzheimer’s disease
Zhang, H., Liu, D., Wang, Y., Huang, H., Zhao, Y., & Zhou, H. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.07.060 · Cited by 41
Bannai, T., Mano, T., Chen, X., Ohtomo, G., Ohtomo, R., Tsuchida, T., Mano, K. K., Hashimoto, T., Okazawa, H., Iwatsubo, T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39494-7 · Cited by 41
Vitamin E, Turmeric and Saffron in Treatment of Alzheimer’s Disease
Adalier, N., & Parker, H. (2016) · Antioxidants · doi:10.3390/antiox5040040 · Cited by 40
iPSC-derived three-dimensional brain organoid models and neurotropic viral infections
Swingler, M., Donadoni, M., Bellizzi, A., Çakır, S., & Sariyer, I. K. (2023) · Journal of NeuroVirology · doi:10.1007/s13365-023-01133-3 · Cited by 43
Sun, Z., Liu, K., Liang, C., Wen, L., Wu, J., Liu, X., & Li, X. (2024) · Phytotherapy Research · doi:10.1002/ptr.8214 · Cited by 43
Xing, Z., Zuo, Z., Hu, D., Zheng, X., Wang, X., Yuan, L., Zhou, L., Qi, F., & Yao, Z. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.09.015 · Cited by 38
Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway
Portelius, E., Mattsson, N., Pannee, J., Zetterberg, H., Gisslén, M., Vanderstichele, H., Gkanatsiou, E., Crespi, G. A. N., Parker, M. W., Miles, L. A., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0152-5 · Cited by 39
Metadata
- Authors
- Baranello, R., Bharani, K., Padmaraju, V., Chopra, N., Lahiri, D., Greig, N., Pappolla, M., & Sambamurti, K.
- Affiliations
- Medical University of South Carolina (US)
- Indiana University – Purdue University Indianapolis (US)
- Indiana University Bloomington (US)
- National Institutes of Health (US)
- The University of Texas Medical Branch at Galveston (US)
- ORCID
- Venue
- Current Alzheimer Research
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2015-01-03
- Volume
- 12
- Issue
- 1
- Pages
- 32-46
- ISSN
- 1567-2050 (ISSN-L)
- PMC
- PMC4820400
- OpenAlex
- W2136334732
- Cited by
- 331
- References
- 201
- Citations by year
- 2026: 9 · 2025: 26 · 2024: 14 · 2023: 30 · 2022: 34 · 2021: 44 · 2020: 45 · 2019: 45 · 2018: 31 · 2017: 22 · 2016: 20 · 2015: 10
- FWCI
- 20.39
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Current Alzheimer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion)
- Funders
- National Institutes of Health (5r21ag042804-02)
- National Institute on Aging (R21-AG042804, AG046200, R01AG022103, R21AG046200, AG042804)
- National Institute of General Medical Sciences (T32 GM08716-13, T32GM008716)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, Alzheimer's disease, amyloid-beta clearance, amyloid beta degradation, amyloid plaques, familial Alzheimer's disease, APP mutations, presenilin, gamma-secretase, BACE1, insulin-degrading enzyme, neprilysin, matrix metalloproteinases, APOE ε4, gamma-secretase inhibitors
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Humans, Models, Biological, Mutation, Signal Transduction, Amyloid beta-Peptides, Presenilin-1, Presenilin-2, Amyloid Precursor Protein Secretases, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
